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Purpose: In children with acute leukemia, bone marrow genetic abnormalities (GA) have prognostic 
significance, and may be the basis for minimal residual disease monitoring. Since April 2007, we have 
used a multiplex reverse transcriptase-polymerase chain reaction tool (HemaVision) to detect of GA. 
Methods: In this study, we reviewed the results of HemaVision screening in 270 children with acute 
leukemia, newly diagnosed at The Catholic University of Korea from April 2007 to December 2011, and 
compared the results with those of fluorescence in situ hybridization (FISH), and G-band karyotyping.
Results: Among the 270 children (153 males, 117 females), 187 acute lymphoblastic leukemia and 
74 acute myeloid leukemia patients were identified. Overall, GA was detected in 230 patients (85.2%). 
HemaVision, FISH, and G-band karyotyping identified GA in 125 (46.3%), 126 (46.7%), and 215 
patients (79.6%), respectively. TEL-AML1 (20.9%, 39/187) and AML1-ETO (27%, 20/74) were the 
most common GA in ALL and AML, respectively. Overall sensitivity of HemaVision was 98.4%, with 
false-negative results in 2 instances: 1 each for TEL-AML1 and MLL-AF4. An aggregate of diseases-
specific FISH showed 100% sensitivity in detection of GA covered by HemaVision for actual probes 
utilized. G-band karyotype revealed GA other than those covered by HemaVison screening in 133 
patients (49.3%). Except for hyperdiplody and hypodiploidy, recurrent GA as defined by the World 
Health Organizationthat were not screened by HemaVision, were absent in the karyotype.
Conclusion: HemaVision, supported by an aggregate of FISH tests for important translocations, may 
allow for accurate diagnosis of GA in Korean children with acute leukemia.
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Introduction
In the recent diagnosis and classification of acute leukemia, genetic characterization, 
rather than morphology-based description, has played a critical role.  A clear example of 
the emphasis on genetic abnormalities (GA) in the diagnosis of hematologic malignancies 
is the inclusion of acute leukemias with “recurrent genetic abnormalities,” as a subdivision 
within the recent World Health Organization (WHO) classification of hematopoietic tumors
1).   
Many of these GA have prognostic utility
2,3), and may form the basis for minimal residual http://dx.doi.org/10.3345/kjp.2013.56.6.247
Kim HJ, et al. • HemaVision for children with acute leukemia
248
disease-based treatment
4).
Methods for evaluation of GA include polymerase chain reac-
tion (PCR)-based molecular methods, and cytogenetic studies 
including fluorescence in situ hybridization (FISH) tests and con-
ventional G-band karyotyping. HemaVision (DNA Techno  logy, 
Aarhus, Denmark) is a method of multiplex reverse transcriptase 
(RT)-PCR that allows for the rapid detection of 28 different GA 
that have been discovered in both acute and chronic leukemia. 
Since the initial report on the utility of this method of multiplex 
RT-PCR screening in acute leukemia
5), several studies have con-
firmed the efficacy of this tool for rapid and sensitive evalua  tion of 
GA in a large number of patients
6-8). Affirmative results of the 
application of the HemaVision tool in the Korean patient popula-
tion have also been reported, with most of the patients tested 
consisting of adults
9-11). However, since an early study on the 
applicability of screening using HemaVision in a cohort of children 
with acute myeloid leukemia (AML)
12), little evaluation of this 
tool has been done in a solely pediatric leukemia patient group, 
and none, so far, has been undertaken in a Korean pediatric pop-
ulation. Considering that the overall incidence of recurrent GA 
may differ between pediatric and adult patients, and considering 
also that the relative incidence of a specific GA may differ 
according to the ethnicity of the patient group studied
13), an 
evaluation of HemaVision in Korean children may yield unique 
results concerning the utility of this tool in detecting GA overall, as 
well as specific GA that may be of greater prognostic significance 
for children.
In this study, we aimed to determine the utility of HemaVision 
in the detection of GA in a cohort of children diagnosed with 
acute leukemia at the Department of Pediatrics, Seoul St. Mary’s 
Hospital, The Catholic University of Korea College of Medicine.
Materials and methods
1. Study cohort
We have utilized HemaVision for the screening of GA in 
patients with acute leukemia since April, 2007. Our study cohort 
consisted of children newly diagnosed with acute leukemia at 
the Department of Pediatrics, The Catholic University of Korea 
from April 2007 to December 2011. Patients who had initially been 
diagnosed at another institution and had received previous 
chemotherapy before referral to our institution were excluded 
from the study cohort. Pertinent patient information, such as age 
at diagnosis, gender, and immunophenotype were retrospectively 
reviewed from medical records. All patients underwent HemaVision 
screening, and cytogenetic tests including an aggregate of disease- 
appropriate FISH tests and G-band karyotyping with bone mar  row 
(BM) samples at the time of diagnosis. The study design received 
approval from the Institutional Review Board (KC12RISI0679).
2. Molecular diagnosis of GA
RNA was extracted from BM samples using High Pure RNA 
Isolation Kit (Roche Diagnostics, Mannheim, Germany). Multiplex 
RT-PCR with HemaVision was done according to manufacturer’s 
instructions, with performance of 2 sequential nested PCR 
reactions, details of which have been published in a previous 
report on HemaVision application
6). The 28 GA screened for by 
HemaVision are shown in Table 1.
3. Cytogenetic studies
An aggregate of interphase FISH tests were done according to 
patient disease. For acute lymphoblastic leukemia (ALL), the fol-
lowing studies were done: BCR-ABL1, TEL-AML1, C-MYC, MLL, 
TCF3. For AML, the following studies were done: BCR-ABL1, 
AML1-ETO, PML-RARA, MLL, CBFB, 5q, 7q31. The probes 
Table 1. The 28 genetic abnormalities screened using the HemaVision 
multiplex reverse transcriptase-polymerase chain reaction
Fusion transcript Chromosomal translocation
BCR-ABL1 t(9;22)(q34;q11)
PML-RARA t(15;17)(q22;q21)
E2A-PBX1 t(1;19)(q23;p13)
TEL-PDGFRB t(5;12)(q33;p13)
CBFB-MYH11 inv(16)(p13;q22) / t(16;16)(p13;q22)
TEL-AML1 t(12;21)(p13;q22)
AML1-ETO t(8;21)(q22;q22)
MLL-AF4 t(4;11)(q21;q23)
MLL-AF6 t(6;11)(q27;q23)
MLL-AF9 t(9;11)(p22;q23)
MLL-AF10 t(10;11)(p12;q23)
MLL-AF17 t(11;17)(q23;q21)
MLL-AF1p t(1;11)(p32;q23)
MLL-AFX t(X;11)(q13;q23)
MLL-ELL t(11;19)(q23;q13.1)
MLL-ENL t(11;19)(q23;p13.3)
MLL-AF1q t(1;11)(q21;q23)
AML-EAP-MDS-EVI1 t(3;21)(q26;q22)
DEK-CAN t(6;9)(p23;q34)
E2A-HLF t(17;19)(q22;p13)
NPM-MLF1 t(3;5)(q25.1;q34)
NPM-RARA t(5;17)(q35;q21)
PLZF-RARA t(11;17)(q23;q21)
SET-CAN t(9;9)(p13;q22)
SIL-TAL1 del(1p34)
TEL-ABL t(9;12)(q34;q13)
TEL-MN1 t(12;22)(p13;q11)
TLS-ERG t(16;21)(p11;q22)249 http://dx.doi.org/10.3345/kjp.2013.56.6.247
Korean J Pediatr 2013;56(6):247-253
used were as follows: LSI BCR/ABL1, RUNX1/RUNX1T1, PML/
RARA dual color, dual fusion translocation probe, LSI ETV6/
RUNX1 extra signal dual color, translocation probe, LSI MYC, 
MLL, CBFB dual color, break apart rearrangement probe, LSI 
EGR1 (5q31)/D5S23 probe, D7S486 (7q31)/CEP7 probe (Abbott 
Laboratories. Abbott Park, IL, USA), and E2A break apart LPS 
019 probe (Cytocell Ltd., Cambridge, UK). The BM cells from 
routine chromosomal preparations were used. Pretreatment and 
hybridization were performed, in accordance with the manufac-
turer’s recommendation. Results were considered abnormal if the 
percentage of nuclei with abnormal signals exceeded the normal 
reference ranges. For the purposes of this study, except for 5q, 
7q31 probes, a FISH test was considered positive if the test aided 
in the identification of a specific translocation, rather than 
incidental numerical abnormalities. The 5q and 7q31 tests were 
considered positive if monosomies or arm deletions of chromo-
somes 5 or 7 were identified.
Chromosomal analysis was performed at diagnosis on short-
term cultures with BM cells at metaphase, according to a conven-
tional G-banding analysis using standard cytogenetic protocols. 
At least 20 metaphases were analyzed in each case, and the 
clonal abnormalities were classified according to International 
System for Chromosome Nomenclature 2009 guidelines
14).
4. Measurements
1) Overall detection of GA in the patient cohort
The overall incidence of GA, detected either through HemaVision, 
FISH or G-band karyotyping, in the patient cohort was evaluated, as 
well as the incidence of GA within each leukemia type and the 
positivity rates of each detection method.
2) Incidence of recurrent GA in the patient cohort
The GA screened by HemaVision include many recurrent 
abnormalities that have prognostic significance. The incidence of 
these recurrent GA within the overall cohort, regardless of diag-
nostic method, and within each leukemia type was determined.
3) Detection of GA with HemaVision and FISH
The positivity rate of HemaVision within each leukemia type, 
and the overall sensitivities of HemaVision and FISH testing in 
detecting GA were assessed.
4) G-band karyotyping
As G-band karyotype analysis may reveal additional informa-
tion concerning numerical and structural chromosomal abnorma-
lities for patients with positive HemaVision tests, the presence of 
such abnormalities in the BM karyotype was noted. Karyotyping 
may also show GA other than those covered by HemaVision 
screening, and the number of patients with such GA was also 
determined.
5) Correlation with WHO classification of recurrent GA in 
acute leukemia
The GA screened by HemaVision coincide significantly with 
the recurrent GA of both ALL and AML that are part of the 2008 
WHO classification
1). However, there are several categories in 
the WHO classification that are not screened by HemaVision: 
hyperdiploidy, hypodiploidy, t(5;14)(q31;q32) for ALL, and 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2), t(1;22)(p13;q13) for AML. 
Our final study objective was to evaluate for the incidence of 
these GA not screened by HemaVision in the karyotype analysis to 
observe whether initial screening with HemaVision allows for 
appropriate patient categorization according to WHO classifica-
tion for recurrent GA.
Results
1. Patient characteristics
Overall, 270 patients (153 males, 117 females) were newly 
diagnosed with acute leukemia at our institution during the 
study period. This cohort consisted of 187 ALL (69.3%), 74 
AML (27.4%), 8 mixed phenotype (MPAL) (3%), and 1 acute 
undifferentiated leukemia patient (0.4%). Amongst the 187 
patients with ALL, 167 were found to have precursor B cell ALL 
according to immunophenotype, while the remaining 20 patients 
were diagnosed with T cell ALL. Median age at diagnosis for the 
study cohort was 6.8 years (range, 0.2 to 18.8 years).
2. Overall detection of GA, and according to each method
Within the entire cohort, 230 patients (85.2%, 230/270) were 
found to have GA either through HemaVision, FISH or karyotype 
study. Forty patients had normal karyotype, and had negative 
findings for both HemaVision and FISH.
With regards to each leukemia type, GA was found in 88.2% 
of ALL patients (165/187), 78.4% of AML patients (58/74), and 
75.0% of MPAL patients (6/8) (Table 2). Of patients with precursor B 
ALL, 88.0% of patients (147/167) were diagnosed with GA, while 
18 of 20 patients (90%) were found to have GA in the T cell 
leukemia subgroup.
HemaVision screening was positive for 16 of 28 possible GA 
in 46.3% of patients (125/270), and FISH in 46.7% (126/270) of 
patients (Table 3). G-band karyotype revealed GA in 215 patients 
(79.6%, 215/270) and proved to have the highest positivity rate 
in terms of detecting GA of all 3 tests.
3. Incidence of recurrent GA screened by HemaVision
Overall, 127 patients were diagnosed with recurrent GA that 
were incorporated into HemaVision screening, through any of 
the 3 test methods. Within the ALL subgroup, 39 patients were 
found to have TEL-AML1, confirming this GA to be the most 
abnormality (20.9%, 39/187). Other recurrent GA diagnosed in 
the ALL subgroup were as follows: BCR-ABL1 (n=17, minor sub-http://dx.doi.org/10.3345/kjp.2013.56.6.247
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type 15, major subtype 2), E2A-PBX1 (n=13), MLL-AF4 (n=9), 
MLL-ENL (n=2), E2A-HLF (n=2), and MLL-AF9 (n=1) for patients 
with precursor B ALL. Minor BCR-ABL1 subtypes included 14 
patients with e1a2, and 1 patient with e1a3 GA. The 2 patients 
with major BCR-ABL1 subtype had b2a2 GA. For patients with T 
cell ALL, 3 patients were found to have recurrent GA, one patient 
each for the following: MLL-ENL, SET-CAN, and SIL-TAL1.
AML1-ETO (n=20) was the most common recurrent GA in the 
AML subgroup, with the remainder consisting of the following: 
PML-RARA (n=9), CBFB-MYH11 (n=6), MLL-AF6 (n=1), MLL-
AF9 (n=1), MLL-AF10 (n=1), MLL-ELL (n=1), and DEK-CAN (n=1).
Amongst the 8 patients with MPAL, 1 patient with T/Myeloid 
phenotype was diagnosed with a SIL-TAL1 abnormality.
4. Results of HemaVision screening and FISH tests
According to leukemia subtype, HemaVision screening was 
positive in 44.9% of ALL (84/187), 54.1% of AML (40/74), and 
1 MPAL patient (Table 2) for a total of 125 positive patients. 
HemaVision was positive in 50.9% of ALL patients with any GA 
(84/165), and 70% of AML patients with any GA (40/58).
The overall sensitivity of HemaVision screening was 98.4% 
(125/127). Of the 2 patients with GA not detected by HemaVision 
were 1 patient with MLL-AF4 confirmed by both FISH and 
karyotype, and 1 patient with TEL-AML1 confirmed by FISH 
alone. A subsequent review of these 2 patients revealed that 
splicing site differences between the fusion transcript detected by 
HemaVision and the actual transcript found in the patients were 
the main reason for the failure of HemaVision screening.
FISH testing showed 100% sensitivity (123/123) in the detection 
of GA covered by HemaVision for actual probes utilized. Besides 
these recurrent GA, testing with FISH (7q31) allowed for the 
diagnosis of 2 AML patients with monosomy 7 and 1 AML patient 
with del(7q) (Table 3).
5. Additional results of G-band karyotype
Of the 125 HemaVision positive patients, the karyotype revealed 
either additional numerical or structural abnormalities in 78 
patients (62.4%), including 20 (16%) with additional numerical 
abnormalities only, 35 (28%) with additional structural abnor-
malities only, and 23 (18.4%) with both additional numerical 
and structural abnormalities. Of the 270 patients in the overall 
cohort, 133 (49.3%) had numerical or structural GA other than 
those covered by HemaVision.
6. HemaVision and the WHO classification of recurrent GA in 
acute leukemia
Hyperdiploidy and hypodiploidy, both categorized as recurrent 
GA in ALL by WHO classification, were identified by G-band 
karyotype in 19.8% (37/187) and 1.1% (2/187) of ALL patients 
respectively. However, other recurrent GA defined by WHO that 
were not covered by HemaVision, (5;14)(q31;q32), inv(3)(q21q 
26.2) or t(3;3)(q21;q26.2), and t(1;22)(p13;q13), were not found 
in karyotype analysis of the overall cohort.
Discussion
Although the data of GA in childhood acute leukemia in this 
Table 2. Genetic abnormalities based on patient diagnosis
Diagnosis No. of patients with 
positive for GA (%)
No. of patients with positive 
HemaVision test (%)
Total no. of 
patients
ALL 165 (88.2) 84 (44.9) 187
Pre-B cell 147 (88.0) 81 (48.5) 167
T cell 18 (90.0) 3 (15.0) 20
AML 58 (78.4) 40 (54.1) 74
MPAL 6 (75.0) 1 (12.5) 8
AUL 1 (100) 0 (0) 1
Total 230 (85.2) 125 (46.3) 270
GA, genetic abnormalities; ALL, acute lymphoblastic leukemia; Pre-B, precursor B 
cell; AML, acute myeloid leukemia; MPAL, mixed phenotype acute leukemia; 
AUL, acute undifferentiated leukemia.
Table 3. Number of patients with genetic abnormalities detected using 
HemaVision, FISH, and G-band karyotyping
Total GA HemaVision FISH Karyotype Total
GA screened by HemaVision
TEL-AML1 38 39 0 39
AML1-ETO 20 20 19 20
BCR-ABL1 17 17 16 17
E2A-PBX1 13 13 13 13
MLL-AF4 8 9 9 9
PML-RARA 9 9 8 9
CBFB-MYH11 6 6 6 6
MLL-ENL 3 3 3 3
MLL-AF9 2 2 2 2
E2A-HLF 2 2 1 2
SIL-TAL1 2 0 0 2
MLL-AF6 1 1 1 1
MLL-AF10 1 1 1 1
MLL-ELL 1 1 1 1
DEK-CAN 1 0 1 1
SET-CAN 1 0 1 1
Subtotal 125 123 82 127
Other GA 0 3* 133
†
Total (%) 125/270 
(46.3)
126/270 
(46.7)
215/270 
(79.6)
FISH, fluorescence in situ hybridization; GA, genetic abnormalities.
*Monosomy 7 and del(7q) as detected by FISH (7q31). 
†Abnormal karyotypes 
except recurrent GA screened by HemaVision.251 http://dx.doi.org/10.3345/kjp.2013.56.6.247
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paper derived from a single Korean institution, several salient 
points can be made with regards to the incidence of specific GA. 
First, nearly 90% of ALL patients were found to have GA. TEL-
AML1, overall the most common GA, was detected in 20.9% of 
ALL patients, indicating an incidence that was similar to figures 
previously reported from Western countries
15). Incidence of GA 
was also high in our AML patients (78.4%). A noteworthy point 
with regards to the incidence of specific GA in our AML patients 
is the significance of AML1-ETO as the most common GA 
(27%, 20/74), in contrast to past studies where incidence of this 
abnormality ranged from 9–12%
16,17). Another clear difference is 
the low rate of combined MLL gene rearrangements in our AML 
cohort (5.4%, 4/74), whereas previous studies have noted an 
approximately 20% incidence for this GA. Prognostic implications 
of these disparities are evident, as detection of AML1-ETO predicts 
a better response to treatment. Although the small number of 
AML patients included in this study do not allow for definite 
conclusions, discrepancies in specific GA incidence hint at the 
possibility of population-based differences that may become 
clear with evaluation of a greater number of Korean AML children.
Overall, 46.3% of patients in the cohort had GA identified 
through HemaVision, a figure which is higher than the 20–30% 
positivity rates reported from cohorts consisting mostly of 
adult patients
8.11). Other studies have analyzed the positivity 
rate of HemaVision within their respective pediatric and adult 
subcohorts and found the rate to be higher in children
6,10). The 
relatively high incidence of GA detected by HemaVision in our 
study may be further evidence of the greater diagnostic signifi-
cance of this tool in children with leukemia, especially AML 
patients in whom HemaVision was positive in 70% of patients 
with any GA, in contrast to the 50.9% positivity rate amongst 
ALL patients with any GA. A note should be made, however, 
concerning the unequal contributions made by each component 
of HemaVision to the overall high detection rate. The 3 most com-
mon GA detected by HemaVision, TEL-AML1, AML1-ETO, BCR-
ABL1, comprised more than half of all positive cases. Twelve of 
28 GA were not represented at all in our cohort. Hence, the high 
positivity rate for HemaVision may stem mostly from high inci-
dence rates of select GA within our cohort.
Besides the relatively high positivity rate and sensitivity shown 
in our study, previously known advantages of HemaVision in-
clude the ability to detect cryptic translocations. In the pediatric 
setting, one of the most important cryptic translocations in terms of 
prognosis would be TEL-AML1 which is not detected in karyo-
type study. Also, in contrast to karyotyping which is a lengthy 
process, HemaVision allows for the rapid identification of impor-
tant GA.  Finally, the RT-PCR method may be deemed cost-effec-
tive, as it allows for the screening of 28 GA at 2–3 times the cost 
of one FISH test, according to current domestic pricing.
HemaVision screening proved to be falsely negative on 2 
occasions: one patient each with TEL-AML1 and MLL-AF4, both 
GA with well-known prognostic significance. In Table 4, we 
have summarized the false-negative results of HemaVision that 
have been reported in the literature. Reasons for false-negative 
results may include differences in splicing sites in the creation 
of the fusion transcript, and lack of mRNA for adequate testing. 
For MLL gene rearrangements, despite the variety of fusion 
transcripts including MLL that are screened for by HemaVision, 
the diversity of MLL partners even within one particular chromo-
some (for example, the numerous fusion partners for MLL on 
17q
11,12)) may elude identification with HemaVision. In our study, 
both false-negative GA were identified through FISH. Hence, 
confirmation of HemaVision results with empirical use of an 
aggregate of FISH tests, including MLL and those that test GA for 
which literature has reported false-negative HemaVision results, 
may lead to the most accurate genetic diagnosis of a leukemia 
patient.
G-band karyotyping allowed for diagnosis of either additional 
numerical or structural abnormalities in 62.4% of patients with 
positive HemaVision tests. The prognostic implications of addi-
tional abnormalities in patients with recurrent GA, as defined by 
WHO, remain unresolved, with several studies concluding that 
additional cytogenetic abnormalities do not alter the prognosis 
conferred by a recurrent GA
18,19). Nevertheless, the identification 
of additional abnormalities in the karyotype forms the basis for 
further studies on their prognostic relevance in the context of 
concurrent GA. Furthermore, karyotype study allowed for the 
identification of GA other than those screened by HemaVision 
in nearly half the patients in the cohort, including monosomies 
and arm deletions which may negatively affect the outcome of 
AML patients. Hence, the G-band karyotype remains an essential 
component for the comprehensive genetic evaluation of the acute 
leukemia patient.
Screening using HemaVision did not allow for full categorization 
according to the 2008 WHO classification for recurrent GA of 
ALL and AML, as HemaVision did not include 5 of these abnor-
malities. However, besides hyperdiploidy and hypodiploidy of 
ALL which were identified in karyotype study, none of the remaining 
Table 4. Summary of published cases reporting false-negative results of 
HemaVision
Study GA (no. of cases with false-negative results) Reference
1 BCR-ABL1 (1) 6
2 PML-RARA (1) 7
3 PML-RARA (3) 9
MLL-AF6 (1)
CBFB-MYH11 (1)
4 MLL-AF4 (1) 10
GA, genetic abnormalities.http://dx.doi.org/10.3345/kjp.2013.56.6.247
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3 abnormalities, that was, t(5;14)(q31;q32), inv(3)(q21q26.2), and 
t(1;22)(p13;q13), were found in our cohort. Hence, in our single 
institution cohort, screening with HemaVision allowed for 
full genetic assessment according to WHO criteria, except for 
numerical abnormalities which could not be tested using an 
RT-PCR based tool. In addition, our study raises the question 
of whether the WHO classification of recurrent abnormalities 
fully reflects the incidence of important genetic aberrations in 
a Korean pediatric population. Of the 3 abnormalities that were 
absent in our cohort, t(1;22)(p13;q13) is known to occur almost 
solely in infants and young children
20), and a nationwide study 
investigating its incidence in Korean AML children may shed 
greater information on its domestic importance.
In conclusion, our experience of screening de novo pediatric 
acute leukemia patients for GA with HemaVision proved to be 
both useful, as 46% of the overall cohort had a positive test, and 
sensitive. Higher positivity rate in our cohort compared to pre-
vious results derived from mostly adult patient-based cohorts 
emphasize the utility of this tool in childhood leukemia.  Greater 
diagnostic accuracy, with relevant prognostic consequences for 
each individual patient, may be achieved by HemaVision screening 
complemented by an aggregate of disease-specific FISH tests, 
especially including MLL and other GA for which false- negative 
HemaVision results have been reported.
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